The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is calling on its members to submit their feedback on recent calls for comment.
According to an email, ISPOR is responding to two calls for comments:
- FDA's Patient-Focused Drug Development guidance document (Dec. 9 deadline); and
- INAMI/RIZIV's real-world evidence paper (Dec. 10 deadline).
To submit comments on the FDA's document, click here.
To submit comments on INAMI/RIZIV's paper, click here.
